<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97581">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02070757</url>
  </required_header>
  <id_info>
    <org_study_id>CXA-NP-11-04</org_study_id>
    <nct_id>NCT02070757</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia</brief_title>
  <acronym>ASPECT-NP</acronym>
  <official_title>A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, Multicenter, Prospective, Randomized study of IV ceftolozane/tazobactam
      vs. IV meropenem  in the treatment of adult patients with either Ventilator-Associated
      Bacterial Pneumonia [VABP] or Ventilated Hospital-Acquired Bacterial Pneumonia [HABP].
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Intent to Treat (ITT) population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult subjects with VNP.</measure>
    <time_frame>This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult subjects with VNP.</measure>
    <time_frame>This will be assessed within 24 hours after EOT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in adult subjects with VNP.</measure>
    <time_frame>LFU occurs 28 to 35 days after EOT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen microbiological response rates of ceftolozane/tazobactam versus meropenem at TOC.</measure>
    <time_frame>This will occur at the TOC which is 7-14 days after EOT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rates of ceftolozane/tazobactam versus meropenem at EOT</measure>
    <time_frame>EOT visit occurs within 24 hours after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had P. aeruginosa from the baseline lower respiratory tract culture</measure>
    <time_frame>TOC is 7-14 days after EOT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated in the safety population by presenting summaries of deaths, AEs, laboratory evaluations, vital signs and physical exam in the 2 treatment groups</measure>
    <time_frame>All study visits through the LFU visit (28-35 days following the EOT visit)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, such as maximum concentration achieved (Cmax), total exposure during one dosing interval (AUC0-τ), steady-state volume of distribution (Vss) and Clearance (CLss)</measure>
    <time_frame>Day 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms in the Microbiological Intent-to-Treat (mITT) population</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had Enterobacteriaceae isolated from the baseline lower respiratory tract culture</measure>
    <time_frame>TOC visit is 7-14 days after EOT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-pathogen clinical response at TOC by baseline minimum inhibitory concentration (MIC) and Kirby-Bauer zone diameter for ceftolozane/tazobactam versus meropenem</measure>
    <time_frame>TOC is 7-14 days after EOT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">726</enrollment>
  <condition>Nosocomial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ceftolozane/tazobactam IV 3000 mg every 8 hours for 8 days, or 14 days for Pseudomonas aeruginosa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>meropenem IV 1000 mg every 8 hours for 8 days, or 14 for Pseudomonas aeruginosa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftolozane/tazobactam</intervention_name>
    <description>Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta(β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.</description>
    <arm_group_label>Ceftolozane/tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.</description>
    <arm_group_label>meropenem</arm_group_label>
    <other_name>Merofit</other_name>
    <other_name>Monan</other_name>
    <other_name>Meronem</other_name>
    <other_name>Merrem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Adult patients diagnosed with either VABP or ventilated HABP requiring IV antibiotic
             therapy

          2. Hospitalized for ≥ 48 hours, intubated and on mechanical ventilation at the time of
             randomization;

          3. APACHE II score between 15 and 35;

          4. New or progressive infiltrate on chest radiography consistent with pneumonia

          5. Presence of clinical criteria consistent with a diagnosis of ventilated nosocomial
             pneumonia

        Key Exclusion Criteria:

          1. History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics

          2. Prior nonstudy antibiotics for &gt; 24 hours

          3. Gram-positive bacteria only on respiratory Gram stain.

          4. Active immunosuppression

          5. End-stage renal disease or requirement for dialysis;

          6. Expected survival &lt; 72 hours

          7. Severe confounding respiratory condition (i.e., chest trauma with paradoxical
             respiration)

          8. Known or suspected community-acquired bacterial pneumonia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Obiamiwe Umeh, M.D., MSc.</last_name>
    <role>Study Director</role>
    <affiliation>Cubist Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Kratz</last_name>
    <phone>267-744-6226</phone>
    <email>Jennifer.Kratz@INCResearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Nygren</last_name>
    <phone>(661) 679-7879</phone>
    <email>Nicole.nygren@INCResearch.com</email>
  </overall_contact_backup>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilator-associated bacterial pneumonia</keyword>
  <keyword>Hospital-acquired bacterial pneumonia</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Infection</keyword>
  <keyword>Ventilator-Induced Lung Injury</keyword>
  <keyword>Lung Injury</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
